Significance of PD-L1 expressing tumor cells in the combined positive score with triple negative breast cancer

被引：0
|
作者：
Evans, Tiffany [1 ]
Hund, Stephanie [1 ]
Krohn, Darlene [1 ]
Emancipator, Kenneth [2 ]
Juco, Jonathon [2 ]
Portier, Bryce [1 ]
Tabuena-Frolli, Siena [1 ]
Kulangara, Karina [1 ]
机构：
[1] Agilent, Carpinteria, CA USA
[2] Merck Sharp & Dohme Corp, Kenilworth, NJ USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS4-15
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Effects of Cardamonin on PD-1/PD-L1 Checkpoint in Triple-Negative Breast Cancer
    Mendonca, Patricia
    Hill, Lonnie
    Soliman, Karam F. A.
    FASEB JOURNAL, 2022, 36
  • [32] PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
    Alkaabi, Duaa
    Arafat, Kholoud
    Sulaiman, Shahrazad
    Al-Azawi, Aya Mudhafar
    Attoub, Samir
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [33] Verteporfin inhibits surface PD-L1 expression in triple-negative breast cancer (TNBC) cells
    Khambati, Fatema
    Jaiswal, Neha
    Chellappan, Srikumar
    Soliman, Hatem
    CANCER RESEARCH, 2018, 78 (13)
  • [34] Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking
    He, Rui
    Yuan, Xing
    Chen, Zeran
    Zheng, Yongfeng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
  • [35] PD1, PD-L1 and PD-L2 mRNA Expression in triple-negative Breast Cancer
    Schueler, K.
    Bethmann, D.
    Staege, M.
    Kantelhardt, J. E.
    Thomssen, C.
    Vetter, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (06) : E24 - E24
  • [36] Change in tumor microenvironment and PD-L1 expression with rucaparib treatment in triple-negative breast cancer.
    Halder, Ritika
    Bhamidipati, Nitish
    Kiss, Alexi
    Aldhahri, Walaa
    Ehsani, Sima
    Segar, Jennifer Margaret
    Foster, Nova
    Chalasani, Pavani
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer
    Chen, Chunhua
    Li, Shiheng
    Xue, Junli
    Qi, Manlong
    Liu, Xin
    Huang, Yan
    Hu, Jinghua
    Dong, Haidong
    Ling, Kun
    JCI INSIGHT, 2021, 6 (08)
  • [38] Intratumoral nanofluidic system enhanced tumor biodistribution of PD-L1 antibody in triple-negative breast cancer
    Liu, Hsuan-Chen
    Capuani, Simone
    Badachhape, Andrew A.
    Di Trani, Nicola
    Gonzalez, Daniel Davila
    Pol, Robin S. Vander
    Viswanath, Dixita I.
    Saunders, Shani
    Hernandez, Nathanael
    Ghaghada, Ketan B.
    Chen, Shu-Hsia
    Nance, Elizabeth
    Annapragada, Ananth V.
    Chua, Corrine Ying Xuan
    Grattoni, Alessandro
    BIOENGINEERING & TRANSLATIONAL MEDICINE, 2023, 8 (06)
  • [39] Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer
    Thongchot, Suyanee
    Jirapongwattana, Niphat
    Luangwattananun, Piriya
    Chiraphapphaiboon, Wannasiri
    Chuangchot, Nisa
    Sa-Nguanraksa, Doonyapat
    O-Charoenrat, Pornchai
    Thuwajit, Peti
    Yenchitsomanus, Pa-Thai
    Thuwajit, Chanitra
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (05) : 727 - 739
  • [40] JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer
    Chen, Meixuan
    Pockaj, Barbara
    Andreozzi, Mariacarla
    Barrett, Michael T.
    Krishna, Sri
    Eaton, Seron
    Niu, Ruifang
    Anderson, Karen S.
    CLINICAL BREAST CANCER, 2018, 18 (05) : E1205 - E1215
12345